Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome

Imagem de Miniatura
Arquivos
art_JAMAL_Cigarette_smoking_worsens_systemic_inflammation_in_persons_with_2014.PDF (366.2 KB)
Citações na Scopus
22
Tipo de produção
article
Data de publicação
2014
Editora
BIOMED CENTRAL LTD
DOI
Indexadores
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Autores
JAMAL, Omar
ANENI, Ehimen C.
SHAHARYAR, Sameer
ALI, Shozab S.
PARRIS, Don
MCEVOY, John W.
VELEDAR, Emir
BLAHA, Michael J.
BLUMENTHAL, Roger S.
AGATSTON, Arthur S.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
DIABETOLOGY & METABOLIC SYNDROME, v.6, article ID 79, 7p, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Emerging data suggests that the combination of smoking and metabolic syndrome (MetS) markedly increases cardiovascular disease risk well beyond that of either condition. In this study we assess if this interaction can be explained by an additive increase in the risk of systemic inflammation by MetS and cigarette smoking. Methods: We evaluated 5,503 healthy non-diabetic Brazilian subjects (mean age of 43 +/- 10 years, 79% males). Participants were divided into sub-groups of smokers and non-smokers with or without MetS. High-sensitivity C reactive protein (hs-CRP) was measured to assess degree of underlying inflammation. Results: Overall (19%) had hs-CRP > 3 mg/L. In adjusted regression analyses, compared to non-smokers, there was a 0.19 mg/L (95% CI: 0.05, 0.32) increase in hs-CRP among smokers in the entire population and 0.63 mg/L (95% CI: 0.26, 1.01) increase among smokers with MetS while there was no significant increase among smokers without MetS (beta = 0.09 95% CI: -0.05, 0.24). In a fully adjusted logistic regression model, smokers compared to non-smokers were 55% more likely to have elevated hs-CRP in the entire population (OR 1.55, 95% CI: 1.25, 1.92) and more than twice as likely to have elevated hs-CRP if they had MetS (OR 2.05, 95% CI: 1.40, 3.01) while the risk was non-significant among those without MetS (OR = 1.29, 95% CI: 0.98, 1.69). Conclusion: The study demonstrates an additive effect of cigarette smoking on the risk of systemic inflammation in MetS thus highlighting the need for determining smoking status among those with MetS and aggressively targeting smoking cessation in this population.
Palavras-chave
Cigarette smoking, Metabolic syndrome, Systemic inflammation, High sensitivity C-reactive protein, Cardiovascular disease risk
URI
https://observatorio.fm.usp.br/handle/OPI/8359
Referências
  1. Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
  2. ATTVALL S, 1993, J INTERN MED, V233, P327
  3. Bazzano LA, 2003, ANN INTERN MED, V138, P891
  4. Beltran-Sanchez H, 1999, J AM COLL CARDIOL, V62, P697
  5. Bermudez EA, 2002, ARTERIOSCL THROM VAS, V22, P1668, DOI 10.1161/01.ATV.0000029781.31325.66
  6. Bermudez EA, 2002, AM J CARDIOL, V89, P1117, DOI 10.1016/S0002-9149(02)02284-1
  7. Borissova AM, 2004, DIABETES METAB, V30, P147, DOI 10.1016/S1262-3636(07)70100-3
  8. Cameron AJ, 2004, ENDOCRIN METAB CLIN, V33, P351, DOI 10.1016/j.ecl.2004.03.005
  9. Adhikari B., 2008, Morbidity and Mortality Weekly Report, V57, P1226
  10. Eliasson B, 1997, EUR J CLIN INVEST, V27, P450, DOI 10.1046/j.1365-2362.1997.1330680.x
  11. Elks CM, 2010, CURR HYPERTENS REP, V12, P99, DOI 10.1007/s11906-010-0096-4
  12. Facchini FS, 1992, LANCET, V339, P1128
  13. Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.2009.2014
  14. Frohlich M, 2003, EUR HEART J, V24, P1365, DOI 10.1016/S0195-668X(03)00260-4
  15. He Y, 2009, J AM COLL CARDIOL, V53, P363, DOI 10.1016/j.jacc.2008.08.073
  16. Howard G, 1998, JAMA-J AM MED ASSOC, V279, P119, DOI 10.1001/jama.279.2.119
  17. Israel DMD A, 2012, MMWR-MORBID MORTAL W, V61, P889
  18. Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140-6736(09)61717-7
  19. Liang LR, 2009, PREV MED, V49, P62, DOI 10.1016/j.ypmed.2009.05.006
  20. Mottillo S, 2010, J AM COLL CARDIOL, V56, P1113, DOI 10.1016/j.jacc.2010.05.034
  21. Ockene IS, 1997, CIRCULATION, V96, P3243
  22. Oh SW, 2005, DIABETES CARE, V28, P2064, DOI 10.2337/diacare.28.8.2064
  23. O'Loughlin J, 2008, NICOTINE TOB RES, V10, P525, DOI 10.1080/14622200801901997
  24. Pickering TG, 2005, HYPERTENSION, V45, P142, DOI 10.1161/01.HYP.0000150859.47929.8e
  25. Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05
  26. Slagter SN, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-195
  27. Sun K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047791
  28. Swinburn BA, 2011, LANCET, V27, P804, DOI 10.1016/S0140-6736(11)60813-1
  29. Wannamethee SG, 2005, EUR HEART J, V26, P1765, DOI 10.1093/eurheartj/ehi183
  30. World Health Organization and World Heart Federation, 2012, GLOB GAPS AW IMPL AC
  31. Zhang LJ, 2013, INT J CARDIOL, V167, P250, DOI 10.1016/j.ijcard.2011.12.079

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - ODS/03